Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Kim D, Chung H, Liu W, Jeong K, Ozmen T, Ozmen F, Rames M, Kim S, Guo X, Jameson N, de Jong P, Yea S, Harford L, Li J, Mathews C, Doroshow D, Charles V, Kim D, Fischer K, Samatar A, Jubb A, Bunker K, Blackwell K, Simpkins F, Meric-Bernstam F, Mills G, Harismendy O, Ma J, Lackner M. Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. Npj Precision Oncology 2025, 9: 3. PMID: 39755818, PMCID: PMC11700143, DOI: 10.1038/s41698-024-00787-4.Peer-Reviewed Original ResearchUterine serous carcinomaSerous carcinomaCyclin E1 expressionOvarian cancer cell linesWEE1 kinase inhibitionE1 expressionPhase I studyClasses of chemotherapyUpregulation of cyclin E1Levels of replication stressIn vivo modelsCancer cell linesGynecologic malignanciesGynecologic cancerOncogenic driversCell cycle checkpointsClinical activityG1 to S phaseBaseline levelsMultiple cell cycle checkpointsActivity of CDK2Cell cycle progressionKinase inhibitionCell linesCyclin E1